Taxinresinol

Taxiresinol: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Names and Classification

Taxiresinol (systematic IUPAC name: a tetrahydrofuranoid lignan; CAS Registry Number: 40951-69-7) is a naturally occurring secondary plant metabolite belonging to the lignan class of polyphenols. Its molecular formula is C₁₉H₂₂O₆, with a molecular weight of 346.38 g/mol. Taxiresinol is a naturally occurring lignan compound primarily found in various plant species, particularly in the Taxus genus, which includes yew trees. It is classified within the phenylpropanoid superfamily, specifically among the tetrahydrofuran-type lignans — a structural subclass defined by an oxygen-bridged five-membered ring formed between two phenylpropane units.

Taxiresinol was previously isolated from the heartwood of T. wallichiana and its structure was established by Mujumdar et al. in 1972 with the help of low-resolution NMR. The absolute configuration of taxiresinol, a lignan from the heartwood of Taxus wallichiana, has been determined as 8R, 8′R, and 7′R with the help of chemical correlation method and X-ray crystallography. Four lignans — (+)-taxiresinol (1), (+)-lariciresinol (2), (−)-secoisolariciresinol (3), and (+)-pinoresinol (4) — were isolated and identified from Taxus cuspidata roots. (+)-Lariciresinol and (−)-secoisolariciresinol were optically pure; (+)-taxiresinol was also suggested to be optically pure.

Taxiresinol is characterized by its complex polyphenolic structure, which contributes to its biological activity. The compound is typically soluble in organic solvents and has limited solubility in water, which is common for many lignans.

1.2 Botanical Sources and Natural Distribution

Taxiresinol is a complex lignan, a type of natural product derived predominantly from plant sources. It is found in several species of coniferous trees and is specifically abundant in the heartwood of Taxus (yew) species. The genus Taxus L. (Taxaceae), commonly known as yew, is widely distributed in the northern hemisphere, occurring in Europe, North America, Eastern Asia, and Asia Minor.

The primary botanical sources from which taxiresinol has been isolated and chemically characterized include:

• Taxus baccata L. (European yew): Lariciresinol and taxiresinol have been isolated from chloroform extract of the heartwood of Taxus baccata L. (Taxaceae). Specifically in T. baccata, five lignans have been found: lariciresinol, taxiresinol, 3′-demethylisolariciresinol-9′-hydroxyisopropylether, isolariciresinol, and 3-demethylisolariciresinol.
• Taxus wallichiana Zucc. (Himalayan yew): The Himalayan yew (Taxus wallichiana Zucc.) is a high-value tree species that naturally grows on either side of the Himalayas. Three lignans — taxiresinol, isotaxiresinol, and (−)-secoisolariciresinol — have been isolated from its heartwood.
• Taxus cuspidata Siebold & Zucc. (Japanese yew): Four lignans, including (+)-taxiresinol, (+)-lariciresinol, (−)-secoisolariciresinol, and (+)-pinoresinol, were isolated and identified from the roots of Taxus cuspidata.
• Taxus yunnanensis Cheng & L.K.Fu (Yunnan yew): Taxiresinol, classified as a tetrahydrofuran-type lignan, has been isolated from the wood of Taxus yunnanensis.
• Perovskia atriplicifolia Benth. (Russian sage): Bioassay-guided phytochemical investigation of the CHCl₃ soluble fraction of the methanol extract of Perovskia atriplicifolia furnished six compounds, including (+)-taxiresinol.
• Pinus spp. (pine trees): Taxiresinol 4′-O-α-L-rhamnoside (TRR) — a glycoside derivative of taxiresinol — was first isolated and identified from red pine (Pinus densiflora Sieb. et Zucc.) twigs, together with other known phenolic compounds.

1.3 Forms, Preparations, and Analytical Detection

In research and reference standard settings, taxiresinol is supplied as a powder, analyzed by HPLC-DAD or HPLC-ELSD, and identified by mass spectrometry and NMR, typically at a purity of 95–99%. Structures of isolated lignans have been elucidated on the basis of spectroscopic methods including IR, EIMS, DCI, 1D and 2D NMR. Taxiresinol is also found as a glycoside: compound 5 was determined to be taxiresinol 4′-O-β-L-rhamnopyranoside, demonstrating that glycosidic forms occur naturally in certain plant species. Recent studies on Taxus extracts from needles found about 50 lignans, including neolignans and a few terpenolignans.

Because taxiresinol is a research-grade phytochemical compound, it is not commercially available as a consumer dietary supplement. It exists in plants as part of complex lignan-rich matrices and is typically extracted using organic solvents (e.g., methanol, chloroform, ethyl acetate). Phytochemical constituents identified in Taxus wallichiana include cephammannine, taxol, taxiresinol, isotaxiresinol, and several other lignans and flavonoids.

2. Traditional and Historical Use

2.1 The Yew Tree in Traditional Medicine Systems

The genus Taxus has a documented history of use in traditional medicine systems across Asia. Taxiresinol has been identified as a constituent of plant materials used in these traditions; however, it is important to note that historical healers did not use isolated taxiresinol — they used whole plant preparations of which taxiresinol was one component among many.

Taxus wallichiana Zucc., known as Himalayan yew, belongs to the family Taxaceae. It is a medium-sized, temperate, Himalayan forest tree of medicinal importance. In India, this evergreen tree is found at altitudes between 1800 and 3300 m above mean sea level. It has been used by native populations for treating common cold, cough, fever, and pain. Its uses are described in Ayurveda and Unani medicine.

In contrast to the European yew (Taxus baccata L.), the Himalayan yew, T. wallichiana, has a remarkable history of medicinal use and is also used as a coloring matter and as incense.

Traditionally, T. wallichiana is used to treat disorders of the digestive, respiratory, nervous, and skeletal systems. Although pharmacologically underexplored, it has been used for antiepileptic, anti-inflammatory, anticancer, antipyretic, and analgesic purposes.

The Himalayan yew is a gymnosperm growing along the Himalayan region of India and adjoining countries. The plant is extensively used by local people for treatment of various diseases such as fever, headache, diarrhea, fractures, and problems of the nervous system. It also finds usage in the Unani system of medicine.

2.2 Chinese Traditional Medicine: Taxus yunnanensis

Taxus yunnanensis, the source of several taxiresinol studies, is found in China and has been referenced in traditional Chinese medicine contexts. Extracts from its wood were historically used for various medicinal purposes, a tradition that provided the ethnobotanical impetus for pharmacological investigation. Besides being the source of taxol, Taxus wallichiana has been investigated for its essential oil, diterpenoids, lignans, steroids, sterols, and biflavonoids.

2.3 Important Caveats Regarding Historical Use

It must be emphasized that the traditional uses documented above concern preparations of yew tree bark, wood, leaves, or heartwood — not isolated taxiresinol. Taxiresinol is one constituent among a complex mixture of phytochemicals in these preparations. The attribution of any specific traditional therapeutic effect to taxiresinol as an individual compound is a modern pharmacological inference, not a documented historical practice. Furthermore, Taxus species are well known to contain highly toxic alkaloids (taxines) in their foliage, bark, and seeds, and traditional uses were carefully circumscribed accordingly.

3. Phytochemistry: Position Among Yew Lignans

3.1 Lignan Structural Class

Taxiresinol belongs to the tetrahydrofuranoid (THF) lignan subclass. Phytochemical investigation of Taxus baccata L. (Taxaceae) by successive chromatographic methods resulted in the isolation of the lignans: lariciresinol (1), taxiresinol (2), 3′-demethylisolariciresinol-9′-hydroxyisopropylether (3), isolariciresinol (4), and 3-demethylisolariciresinol (5), as well as taxoids. These compounds were evaluated for their several biological activities such as anti-inflammatory, antinociceptive, anti-ulcerogenic, antimicrobial, cytotoxic, antioxidant, and acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and lipoxygenase (LOX) inhibitory activities.

Co-occurring structural relatives of taxiresinol in Taxus species include isotaxiresinol, lariciresinol, isolariciresinol, secoisolariciresinol, and pinoresinol — all members of the same lignan family but with differing stereochemical configurations and substitution patterns. Anticancer activity has been detected for three lignans isolated from the heartwood of T. wallichiana: taxiresinol 1, isotaxiresinol 2, and (−)-secoisolariciresinol 3.

3.2 Isolation and Extraction

Taxiresinol is predominantly extracted from the heartwood or wood of Taxus species. The isolation process typically involves sequential solvent extraction (using water, methanol, ethyl acetate, or chloroform) followed by chromatographic purification. Taxiresinol and (7′R)-7′-hydroxylariciresinol are two tetrahydrofuran-type lignans isolated from the wood of Taxus yunnanensis. In Perovskia atriplicifolia, taxiresinol was obtained from the CHCl₃ soluble fraction of a methanol extract through bioassay-guided fractionation.

4. Mechanisms of Action

4.1 Antioxidant Mechanisms

Taxiresinol possessed strong DPPH radical scavenging activity (IC₅₀ 18.4 μM), superior to that of the well-known antioxidant caffeic acid (IC₅₀ 25.5 μM) and comparable to the activity of ascorbic acid (IC₅₀ 12.6 μM). This activity is attributed to the compound's polyphenolic hydroxyl groups, which are capable of donating hydrogen atoms to quench free radicals — a mechanism common to the broader lignan and polyphenol classes.

Taxiresinol exhibits antioxidant properties, which can help in neutralizing free radicals and reducing oxidative stress in biological systems.

4.2 Anti-inflammatory Mechanisms

Taxiresinol has been shown to modulate multiple inflammatory pathways:

• Leukotriene C4 (LTC4) inhibition: (+)-Taxiresinol was evaluated for its inhibitory activity on LTC4 release and exhibited the most potent inhibition of LTC4 release among tested compounds, with an IC₅₀ value of 3.4 ± 0.09 µM (the positive control zileuton had an IC₅₀ of 0.77 ± 0.05 µM).
• Nitric oxide inhibition: Taxiresinol showed moderate inhibitory activity of NO production in LPS-activated RAW264.7 cells.
• Carrageenan model: Taxiresinol weakened the carrageenan-induced inflammatory process by reducing the swelling thickness of the hind paw by 27%.

4.3 Hepatoprotective Mechanisms

Taxiresinol can protect hepatocytes from apoptosis via an inhibition of TNF-alpha production by activated macrophages and a direct inhibition of apoptosis induced by TNF-alpha in D-GalN/LPS-treated mice. This dual mechanism — targeting both upstream macrophage-mediated cytokine release and downstream apoptotic signaling in hepatocytes — accounts for the compound's hepatoprotective profile as observed in preclinical animal studies.

4.4 Cellular Pathway Modulation

The mode of action of taxiresinol involves modulation of cellular pathways through its interaction with enzymes and receptor sites, influencing oxidative stress and cellular differentiation. This interaction can lead to alterations in signal transduction pathways, which are crucial in cell development, apoptosis, and proliferation.

5. Scientific Evidence by Area of Use

Important note on evidence level: As of the available published literature, all experimental studies on taxiresinol involve in vitro (cell culture) or in vivo (animal model) experimentation. No published human clinical trials, randomized controlled trials, or systematic reviews evaluating taxiresinol as an isolated compound in human subjects have been identified. All findings below are therefore preclinical in nature, and their translational relevance to human health remains unestablished.

5.1 Anticancer Activity

Evidence level: In vitro only — preliminary and exploratory.

The anticancer activity of taxiresinol 1 and two other lignans was studied, and taxiresinol 1 showed notable anticancer activity in the in vitro bioassays against colon, liver, ovarian, and breast cancer cell lines. This finding was reported by Chattopadhyay et al. (2003, Bioorganic & Medicinal Chemistry), who also used the study to determine the compound's absolute stereochemistry. Anticancer activity was detected for three lignans isolated from the heartwood of T. wallichiana.

Limitations: All anticancer data for taxiresinol is derived from in vitro cell line experiments. No in vivo tumor models, pharmacokinetic studies, or human trials have been reported. In vitro cytotoxicity data cannot be directly extrapolated to clinical efficacy or safety in humans.

5.2 Hepatoprotective (Liver-Protective) Activity

Evidence level: In vivo (animal) — preclinical only.

The hepatoprotective effect of taxiresinol, a tetrahydrofuran-type lignan isolated from the wood of Taxus yunnanensis, was investigated on D-galactosamine (D-GalN)/lipopolysaccharide (LPS)-induced hepatic liver injury in mice. Pre-administration at doses of 50 and 10 mg/kg (intraperitoneal) at 12 and 1 hour before D-GalN/LPS injection significantly inhibited hepatocyte DNA fragmentation and apoptotic body formation. Pre-treatment further suppressed hepatic necrosis, demonstrated by significant and dose-dependent reduction in serum GPT and GOT at 8 hours after intoxication.

The elevation of serum tumor necrosis factor-alpha (TNF-alpha) level by D-GalN/LPS toxication was significantly inhibited by taxiresinol at doses of 50 and 10 mg/kg. This study, published in Planta Medica (Nguyen et al., 2004), provides mechanistic insight into the hepatoprotective effect.

Limitations: This is a mouse model study using intraperitoneal (not oral) administration for the primary endpoints. The model (D-GalN/LPS-induced hepatitis) is a specific acute chemical injury model and may not reflect common human liver diseases. No human studies exist.

5.3 Anti-ulcerogenic (Gastroprotective) Activity

Evidence level: In vivo (animal) — preclinical only.

Four lignan-type compounds — lariciresinol, taxiresinol, isolariciresinol, and 3-demethylisolariciresinol — were isolated from the heartwood of Taxus baccata L. growing in Turkey. In vivo anti-ulcerogenic potency of these compounds was investigated on an ethanol-induced ulcerogenesis model in rats at two different doses, 50 and 100 mg/kg. All compounds were shown to possess significant anti-ulcerogenic activity at both doses; however, the effect of taxiresinol was the most prominent.

This study (Gurbuz et al., 2004, Zeitschrift für Naturforschung C) used a standard animal model of acute gastric ulceration; the results suggest gastric mucosal protection but have not been replicated in human subjects.

5.4 Anti-inflammatory and Antinociceptive Activity

Evidence level: In vitro and in vivo (animal) — preclinical only.

Phytochemical investigation of Taxus baccata L. resulted in the isolation of taxiresinol and related lignans, which were evaluated for their anti-inflammatory, antinociceptive, anti-ulcerogenic, antimicrobial, cytotoxic, antioxidant, and AChE, BChE, and lipoxygenase (LOX) inhibitory activities.

Four taxoids and five lignans — including taxiresinol — were isolated from the heartwood of Taxus baccata L. growing in Turkey. In vivo anti-inflammatory and antinociceptive activity of these compounds was investigated. All compounds were shown to possess significant antinociceptive activity against p-benzoquinone-induced abdominal contractions, while only lignan derivatives significantly inhibited carrageenan-induced hind paw edema in mice.

A key mechanistic study in Perovskia atriplicifolia (Ahmad et al., 2015, Pharmaceutical Biology) showed that (+)-taxiresinol exhibited the most potent inhibition of LTC4 release among tested compounds, with an IC₅₀ value of 3.4 ± 0.09 µM, compared with zileuton (IC₅₀ 0.77 ± 0.05 µM) as the positive control, and other tested lignans ranging from 7.9 to 17.2 µM.

Limitations: All antinociceptive and anti-inflammatory data are from animal models (mice and rats) or cell lines. These data demonstrate biological plausibility but cannot be used to infer efficacy in human pain or inflammatory conditions. No clinical trials have been published.

5.5 Antiallergic / Antihistamine Activity

Evidence level: In vitro only — preliminary.

The H₂O and H₂O/MeOH (1:1) extracts from the wood of Taxus yunnanensis showed a remarkable inhibitory effect on induced histamine release from the human basophilic cell line KU812. Eleven constituents purified from the wood extracts were tested by an in vitro histamine release inhibition assay. Among them, secoisolariciresinol and taxiresinol were found to show inhibitory activities. This study was published in Biological and Pharmaceutical Bulletin (2006).

Limitations: Inhibition of histamine release from a human basophilic cell line (KU812) is an in vitro model. Although the cell line is of human origin, this cannot be translated into clinical antiallergic efficacy without further pharmacokinetic, pharmacodynamic, and clinical study.

5.6 Antioxidant Activity

Evidence level: In vitro only — well-characterized but not clinically validated.

Taxiresinol possessed strong DPPH radical scavenging activity (IC₅₀ 18.4 μM), superior to that of the well-known antioxidant caffeic acid (IC₅₀ 25.5 μM) and comparable to the activity of ascorbic acid (IC₅₀ 12.6 μM). These results, reported in a 2022 systematic review in the journal International Journal of Molecular Sciences (Metsämuuronen & Sirén-type review in MDPI), confirm potent in vitro antioxidant capability, consistent with the compound's polyphenolic structure.

5.7 Potential Antidiabetic Activity (In Silico)

Evidence level: In silico (computational) only — very preliminary.

In a computational study, selected compounds from Perovskia atriplicifolia — including taxiresinol — were evaluated for antidiabetic potential using molecular docking simulations. All selected compounds possessed moderate to strong respective activities against aldose reductase, DPP-IV, PTPB, insulin receptor, and PPAR-γ. Taxiresinol showed a binding energy of ΔG = −7.6 kcal/mol against PPAR-γ.

Limitations: In silico docking data represent a computational prediction only and do not constitute biological or clinical evidence of antidiabetic activity. No cell-based or animal-based antidiabetic studies with isolated taxiresinol have been identified in the available literature.

6. Body Systems and Health Areas of Association

Based on the available preclinical scientific literature, taxiresinol has been investigated in connection with the following body systems:

• Hepatobiliary system: Hepatoprotective effects demonstrated in animal models, mediated through TNF-alpha suppression and anti-apoptotic mechanisms.
• Gastrointestinal system: Anti-ulcerogenic activity in rat gastric ulcer models, with taxiresinol exhibiting the most prominent effect among co-isolated yew lignans.
• Immune and inflammatory system: Inhibition of leukotriene C4 release, nitric oxide production, and carrageenan-induced edema in preclinical models.
• Oncology (in vitro): Cytotoxic activity against cell lines derived from colon, liver, ovarian, and breast cancers.
• Allergic response (in vitro): Inhibition of histamine release from human basophilic cells.
• Antioxidant protection: Free radical scavenging in biochemical assays.
• Metabolic (computational): Predicted interactions with antidiabetic molecular targets.

7. Dosages Reported in Studies

The following dosages are reported only as used in the cited experimental studies. These are research dosages in animal models and should not be construed as therapeutic recommendations.

• Hepatoprotective (mouse, intraperitoneal): Pre-administration of taxiresinol at doses of 50 and 10 mg/kg (i.p.) at 12 and 1 hour before D-GalN/LPS injection significantly inhibited hepatocyte DNA fragmentation and apoptotic body formation.
• Hepatoprotective (TNF-alpha suppression, mouse): The elevation of serum tumor necrosis factor-alpha level by D-GalN/LPS toxication was significantly inhibited by taxiresinol at doses of 50 and 10 mg/kg.
• Anti-ulcerogenic (rat, in vivo): In vivo anti-ulcerogenic potency was investigated on an ethanol-induced ulcerogenesis model in rats at two different doses: 50 and 100 mg/kg.
• LTC4 inhibition (in vitro, cell-based): (+)-Taxiresinol exhibited the most potent inhibition of LTC4 release with an IC₅₀ value of 3.4 ± 0.09 µM.
• DPPH radical scavenging (in vitro): DPPH radical scavenging activity IC₅₀ of 18.4 μM.

No human dosage data for taxiresinol exist in the published literature. The compound is not commercially available as a human supplement, and no clinical pharmacokinetic studies have been published.

8. Safety Considerations

8.1 The Context of Taxus Species Toxicity

Any consideration of the safety of taxiresinol must be framed within the well-established toxicity profile of the genus Taxus. The yew tree (Taxus spp.) is a dicot gymnosperm belonging to the Taxaceae family and can be found in America, Europe, and Asia. These trees have in their bark and leaves diterpenic alkaloids known as taxoids, which are chemically characterized by the presence of a taxane skeleton and an oxetane ring, such as taxol, used in the treatment of cancer. The highly toxic taxine alkaloids present in most parts of Taxus species (excluding the aril) have caused fatal poisonings in humans and livestock, making any oral use of crude yew preparations extremely hazardous. Taxiresinol as an isolated lignan compound is chemically distinct from taxine alkaloids; however, no direct human safety data for isolated taxiresinol have been published.

8.2 Absence of Clinical Toxicology Data

No formal toxicological studies — including acute toxicity, subchronic or chronic toxicity, genotoxicity, reproductive toxicity, or carcinogenicity studies — specifically evaluating isolated taxiresinol have been identified in the peer-reviewed literature. The compound is catalogued by research chemical suppliers explicitly as a reference standard for laboratory use only, with the notation "not for human use." Products containing isolated taxiresinol are designated for reference standard and R&D purposes, not for direct human use.

8.3 Lignan Class General Considerations

As a lignan, taxiresinol is structurally related to secoisolariciresinol diglucoside (SDG) from flaxseed and other dietary lignans that undergo enterolignin conversion in the gut. However, taxiresinol's specific metabolic fate, bioavailability, and potential for drug interactions in humans are entirely unknown, as no relevant pharmacokinetic studies have been published in the accessible literature.

8.4 Known Biological Activities with Safety Implications

Preclinical evidence shows that taxiresinol potently inhibits leukotriene C4 production. Compounds including taxiresinol were found to possess inhibitory activity on LTC4 and seem to have potential therapeutic effect on inflammatory diseases. At the same time, LTC4 inhibition at physiologically significant concentrations could theoretically interact with leukotriene-mediated physiological processes; this remains entirely untested in humans.

9. Current Research Status and Limitations

Taxiresinol remains an early-stage research compound. It has been studied for its potential anti-inflammatory and anticancer effects, making it of interest in pharmacological research. Overall, taxiresinol represents a significant area of study in natural product chemistry and its potential applications in health and medicine.

The primary gaps in knowledge that limit conclusions about taxiresinol's health value include:

• Complete absence of human pharmacokinetic data (oral bioavailability, metabolism, half-life, tissue distribution).
• No clinical trial data of any phase.
• No formal toxicological assessment at the isolated compound level.
• Limited in vivo animal data, with studies predominantly conducted in acute injury models rather than chronic disease models.
• Uncertainty about whether in vitro IC₅₀ values (µM range) are achievable in vivo through oral administration.

The plant source has been explored for anti-inflammatory, analgesic, antipyretic, anticonvulsant, immunomodulatory, hepatoprotective, and anticancer activity with satisfactory outcome in preclinical settings. Whether taxiresinol specifically is responsible for these effects in complex plant extracts, or whether synergistic lignan mixtures are required, has not been determined.

References

• PubChem. Taxiresinol | C19H22O6 | CID 10088963. National Center for Biotechnology Information.
• Chattopadhyay SK, et al. (2003). Absolute configuration and anticancer activity of taxiresinol and related lignans of Taxus wallichiana. Bioorganic & Medicinal Chemistry, 11(23), 4945–4948.
• Nguyen NT, et al. (2004). Hepatoprotective effect of taxiresinol and (7′R)-7′-hydroxylariciresinol on D-galactosamine and lipopolysaccharide-induced liver injury in mice. Planta Medica. PubMed PMID: 14765289.
• Gurbuz I, Erdemoglu N, Yesilada E, Sener B. (2004). Anti-ulcerogenic lignans from Taxus baccata L. Zeitschrift für Naturforschung C, 59(3–4), 233–236.
• Antiallergic activity of aqueous extracts and constituents of Taxus yunnanensis. PubMed PMID: 17077536. Biological and Pharmaceutical Bulletin (2006).
• Metsämuuronen S, Sirén H. (2022). Lignans as pharmacological agents in disorders related to oxidative stress and inflammation: Chemical synthesis approaches and biological activities. International Journal of Molecular Sciences, 23(11), 6031. PMC9181380.
• Ethnomedical Properties of Taxus wallichiana Zucc. (Himalayan Yew). PMC4142453.
• Erdemoglu N, Sener B. (2004). Structural and spectroscopic characteristics of two lignans from Taxus baccata L. Bioorganic & Medicinal Chemistry.
• Phenolic constituents of Taxus cuspidata I: lignans from the roots. Journal of Wood Science.
• Ahmad I, et al. (2015). Anti-inflammatory constituents from Perovskia atriplicifolia. Pharmaceutical Biology. PubMed PMID: 25856716.
• In Silico Analysis of Compounds Derived from Perovskia atriplicifolia for their Antidiabetic Potential. Bentham Science.
• Kim JH, et al. (2022). Quantitative Changes of Phenolic Compounds in Pine Twigs by Variety, Harvest Season, and Growing Region. Preventive Nutrition and Food Science. PMC9585405.
• A review of traditional use, phytoconstituents and biological activities of Himalayan yew, Taxus wallichiana. Chinese Journal of Natural Medicines.
• Ethnobotanical and pharmacological importance of Taxus wallichiana Zucc. Plant Science Today.
• Ethnomedical Properties of Taxus wallichiana Zucc. (Himalayan Yew). Asian Pacific Journal of Tropical Biomedicine.